Francesco Parlati

10.6k total citations · 4 hit papers
52 papers, 7.5k citations indexed

About

Francesco Parlati is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Francesco Parlati has authored 52 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 16 papers in Oncology and 15 papers in Cell Biology. Recurrent topics in Francesco Parlati's work include Ubiquitin and proteasome pathways (15 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Cellular transport and secretion (11 papers). Francesco Parlati is often cited by papers focused on Ubiquitin and proteasome pathways (15 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Cellular transport and secretion (11 papers). Francesco Parlati collaborates with scholars based in United States, Canada and Switzerland. Francesco Parlati's co-authors include James A. McNew, Thomas Söllner, James E. Rothman, Thomas Weber, Benedikt Westermann, Boris V. Zemelman, Michael Gmachl, Mark K. Bennett, Ryouichi Fukuda and Susan D. Demo and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Francesco Parlati

51 papers receiving 7.4k citations

Hit Papers

SNAREpins: Minimal Machinery for Membrane Fusion 1998 2026 2007 2016 1998 2014 2007 2000 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SNAREpins: Minimal Machinery for Membrane Fusion
    1998 2.0k citations Thomas Weber, Boris V. Zemelman et al. Cell profile →
  2. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
    2014 797 citations Matt I. Gross, Susan D. Demo et al. Molecular Cancer Therapeutics profile →
  3. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
    2007 542 citations Susan D. Demo, Christopher J. Kirk et al. Cancer Research profile →
  4. Compartmental specificity of cellular membrane fusion encoded in SNARE proteins
    2000 537 citations James A. McNew, Francesco Parlati et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Parlati United States 27 6.0k 3.9k 1.0k 922 693 52 7.5k
Sima Lev Israel 43 5.2k 0.9× 2.3k 0.6× 958 0.9× 597 0.6× 308 0.4× 81 8.0k
Michael Fry United Kingdom 46 8.7k 1.5× 2.2k 0.6× 1.3k 1.3× 754 0.8× 422 0.6× 99 10.8k
Nina Marie Pedersen Norway 38 2.7k 0.4× 1.5k 0.4× 882 0.9× 883 1.0× 388 0.6× 75 4.6k
Namrata D. Udeshi United States 37 7.7k 1.3× 3.0k 0.8× 1.1k 1.1× 356 0.4× 763 1.1× 81 10.0k
Marc Symons United States 54 8.9k 1.5× 4.6k 1.2× 2.3k 2.2× 1.4k 1.5× 327 0.5× 136 12.7k
Clare E. Futter United Kingdom 49 4.7k 0.8× 3.2k 0.8× 1.1k 1.1× 570 0.6× 166 0.2× 98 8.3k
Victor A. Fried United States 33 6.3k 1.0× 2.2k 0.6× 1.4k 1.4× 481 0.5× 401 0.6× 53 8.3k
Shigeyuki Nada Japan 34 4.7k 0.8× 1.5k 0.4× 853 0.8× 380 0.4× 239 0.3× 71 6.8k
Hugh F. Paterson United Kingdom 35 8.0k 1.3× 3.8k 1.0× 1.8k 1.7× 624 0.7× 236 0.3× 41 10.6k
Kent L. Rossman United States 37 6.9k 1.1× 2.8k 0.7× 1.5k 1.5× 641 0.7× 158 0.2× 51 8.8k

Countries citing papers authored by Francesco Parlati

Since Specialization
Citations

This map shows the geographic impact of Francesco Parlati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Parlati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Parlati more than expected).

Fields of papers citing papers by Francesco Parlati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Parlati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Parlati. The network helps show where Francesco Parlati may publish in the future.

Co-authorship network of co-authors of Francesco Parlati

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Parlati. A scholar is included among the top collaborators of Francesco Parlati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Parlati. Francesco Parlati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Emberley, Ethan, Alison Pan, Jason Chen, et al.. (2021). The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. PLoS ONE. 16(11). e0259241–e0259241. 33 indexed citations
2.
Cobo, Ana Galan, Piyada Sitthideatphaiboon, Xiao Qu, et al.. (2019). LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS -Mutant Lung Adenocarcinoma. Cancer Research. 79(13). 3251–3267. 215 indexed citations
3.
Works, Melissa, Mark K. Bennett, Ethan Emberley, et al.. (2016). Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response. Cancer Research. 76(14_Supplement). 552–552. 10 indexed citations
4.
MacKinnon, Andrew L., Mark K. Bennett, Matt Gross, et al.. (2015). Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma. Blood. 126(23). 1802–1802. 4 indexed citations
5.
Zhou, Han-Jie, Jinhai Wang, Bing Yao, et al.. (2015). Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). Journal of Medicinal Chemistry. 58(24). 9480–9497. 146 indexed citations
6.
Gross, Matthew, Jason Chen, Ethan Emberley, et al.. (2015). Abstract A195: CB-1158 inhibits the immuno-oncology target arginase and causes an immune mediated anti-tumor response. Molecular Cancer Therapeutics. 14(12_Supplement_2). A195–A195. 4 indexed citations
7.
Gross, Matt I., Susan D. Demo, Jennifer B. Dennison, et al.. (2014). Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 13(4). 890–901. 797 indexed citations breakdown →
8.
MacKinnon, Andrew L., Mark K. Bennett, Mirna L.M. Rodriguez, & Francesco Parlati. (2014). Biomarkers of Response to the Glutaminase Inhibitor CB-839 in Multiple Myeloma Cells. Blood. 124(21). 3429–3429. 2 indexed citations
9.
Parlati, Francesco, Julie Janes, Evan R. Lewis, et al.. (2014). Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models. Blood. 124(21). 4720–4720. 7 indexed citations
10.
Parlati, Francesco, Susan D. Demo, Julie Janes, et al.. (2013). Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances. Blood. 122(21). 4226–4226. 21 indexed citations
11.
Arastu‐Kapur, Shirin, Janet L. Anderl, Marianne Kraus, et al.. (2011). Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clinical Cancer Research. 17(9). 2734–2743. 329 indexed citations
12.
Muchamuel, Tony, Michael Basler, Monette Aujay, et al.. (2009). A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Medicine. 15(7). 781–787. 494 indexed citations
13.
Huang, Xiangao, Kathryn A. Bailey, Maurizio Di Liberto, et al.. (2008). Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047. Blood. 112(11). 3670–3670. 3 indexed citations
14.
Demo, Susan D., Christopher J. Kirk, Monette Aujay, et al.. (2007). Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome. Cancer Research. 67(13). 6383–6391. 542 indexed citations breakdown →
15.
Varlamov, Oleg, Allen Volchuk, Claudia A. Doege, et al.. (2003). i-SNAREs. The Journal of Cell Biology. 164(1). 79–88. 66 indexed citations
16.
Wong, Brian, Francesco Parlati, Kunbin Qu, et al.. (2003). Drug discovery in the ubiquitin regulatory pathway. Drug Discovery Today. 8(16). 746–754. 51 indexed citations
17.
Parlati, Francesco, James A. McNew, Ryouichi Fukuda, et al.. (2000). Topological restriction of SNARE-dependent membrane fusion. Nature. 407(6801). 194–198. 223 indexed citations
18.
Fukuda, Ryouichi, James A. McNew, Thomas Weber, et al.. (2000). Functional architecture of an intracellular membrane t-SNARE. Nature. 407(6801). 198–202. 204 indexed citations
19.
Weber, Thomas, Boris V. Zemelman, James A. McNew, et al.. (1998). SNAREpins: Minimal Machinery for Membrane Fusion. Cell. 92(6). 759–772. 2013 indexed citations breakdown →
20.
Vernet, Thierry, Robert Ménard, Francesco Parlati, et al.. (1991). Engineering of papain: selective alteration of substrate specificity by site-directed mutagenesis. Biochemistry. 30(37). 8929–8936. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sima Lev Breakdown of academic impact, for papers by Michael Fry Breakdown of academic impact, for papers by Nina Marie Pedersen Breakdown of academic impact, for papers by Namrata D. Udeshi Breakdown of academic impact, for papers by Marc Symons Breakdown of academic impact, for papers by Clare E. Futter Breakdown of academic impact, for papers by Victor A. Fried Breakdown of academic impact, for papers by Shigeyuki Nada Breakdown of academic impact, for papers by Hugh F. Paterson Breakdown of academic impact, for papers by Kent L. Rossman
Rankless by CCL
2026